Flumazenil for the Treatment of Refractory Hypersomnolence: Clinical Experience with 153 Patients.
暂无分享,去创建一个
[1] A. Reece,et al. Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System. , 2015, Current pharmaceutical design.
[2] Y. Baruch,et al. Pharmacokinetics and Safety of Sublingual Flumazenil (CRLS035) in Healthy Adults (Potential Therapy for Hepatic Encephalopathy) , 2014 .
[3] A. Jenkins,et al. Improvement in daytime sleepiness with clarithromycin in patients with GABA-related hypersomnia: Clinical experience , 2014, Journal of psychopharmacology.
[4] J. Golmard,et al. Effects of pitolisant, a histamine H3 inverse agonist, in drug-resistant idiopathic and symptomatic hypersomnia: a chart review. , 2014, Sleep medicine.
[5] G. Hulse,et al. Use of subcutaneous flumazenil preparations for the treatment of idiopathic hypersomnia: A case report , 2014, Journal of psychopharmacology.
[6] J. Melichar,et al. Benzodiazepine dependence and its treatment with low dose flumazenil , 2014, British journal of clinical pharmacology.
[7] G. Hulse,et al. Withdrawal and psychological sequelae, and patient satisfaction associated with subcutaneous flumazenil infusion for the management of benzodiazepine withdrawal: a case series , 2013, Journal of psychopharmacology.
[8] Jacqueline A. Fairley,et al. Modulation of Vigilance in the Primary Hypersomnias by Endogenous Enhancement of GABAA Receptors , 2012, Science Translational Medicine.
[9] E. Mignot. A Practical Guide to the Therapy of Narcolepsy and Hypersomnia Syndromes , 2012, Neurotherapeutics.
[10] T. Morgenthaler,et al. Idiopathic hypersomnia: clinical features and response to treatment. , 2009, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.
[11] Cathy Alessi,et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. , 2007, Sleep.
[12] D. Arand,et al. Treatment of narcolepsy and other hypersomnias of central origin. , 2007, Sleep.
[13] L. Sharples,et al. Idiopathic hypersomnia: a study of 77 cases. , 2007, Sleep.
[14] E. Bullmore,et al. Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia. , 2007, Archives of general psychiatry.
[15] W. Ondo,et al. Intravenous flumazenil for Parkinson's disease: A single dose, double blind, placebo controlled, cross‐over trial , 2006, Movement disorders : official journal of the Movement Disorder Society.
[16] P. Fonagy,et al. The effects of the benzodiazepine antagonist Ro 15-1788 on psychophysiological performance and subjective measures in normal subjects , 2006, Psychopharmacology.
[17] L. Gluud,et al. Benzodiazepine receptor antagonists for hepatic encephalopathy. , 2004, The Cochrane database of systematic reviews.
[18] R. Lambe,et al. Absence of central effects in man of the benzodiazepine antagonist Ro 15-1788 , 2004, Psychopharmacology.
[19] A. Scholey,et al. A randomised, controlled trial of cognitive and psychomotor recovery from midazolam sedation following reversal with oral flumazenil , 2002, Anaesthesia.
[20] J. W. A. S. Sander,et al. The effect of oral flumazenil on interictal epileptic activity: results of a double-blind, placebo-controlled study , 1993, Epilepsy Research.
[21] D. Greenblatt,et al. The International Classification of Sleep Disorders , 1992 .
[22] W. Spivey,et al. Flumazenil and seizures: analysis of 43 cases. , 1992, Clinical therapeutics.
[23] P. Ferenci,et al. Successful long-term treatment of portal-systemic encephalopathy by the benzodiazepine antagonist flumazenil. , 1989, Gastroenterology.
[24] R. Meier,et al. Treatment of hepatic encephalopathy (HE) with the benzodiazepine antagonist flumazenil: a pilot study. , 1988, European journal of anaesthesiology. Supplement.
[25] G. Scollo-Lavizzari. The clinical anti-convulsant effects of flumazenil, a benzodiazepine antagonist. , 1988, European journal of anaesthesiology. Supplement.
[26] W. Ziegler,et al. Pharmacokinetics of the new benzodiazepine antagonist Ro 15-1788 in man following intravenous and oral administration. , 1986, British journal of clinical pharmacology.